CORDIS
EU research results

CORDIS

English EN
Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Objective

Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for real-world digital mobility assessment; to validate digital outcomes in predicting clinical outcome in chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, proximal femoral fracture recovery and congestive heart failure; and, to obtain key regulatory and health stakeholder approval for digital mobility assessment. The objectives address the call directly by linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice. MOBILISE-D consists of 35 partners from 13 countries with long, successful collaboration, combining the requisite expertise to address the technical and clinical challenges. To achieve the objectives, partners will jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes can successfully predict relevant clinical outcomes and provide a better, safer and quicker way to arrive at the development of innovative medicines. MOBILISE-D's results will directly facilitate drug development, and establish the roadmap for clinical implementation of new, complementary tools to identify, stratify and monitor disability, so enabling widespread, cost-effective access to optimal clinical mobility management through personalised healthcare.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY OF NEWCASTLE UPON TYNE

Address

Kings Gate
Ne1 7ru Newcastle Upon Tyne

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 3 856 400

Participants (33)

Sort alphabetically

Sort by EU Contribution

Expand all

THE UNIVERSITY OF SHEFFIELD

United Kingdom

EU Contribution

€ 2 094 841,25

THE FOUNDATION FOR MEDICAL RESEARCH INFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV

Israel

EU Contribution

€ 1 117 625

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Germany

EU Contribution

€ 973 943,75

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA

Italy

EU Contribution

€ 855 665

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 833 536,25

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Switzerland

EU Contribution

€ 993 625

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG

Germany

EU Contribution

€ 847 863,75

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 1 484 050

NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU

Norway

EU Contribution

€ 2 163 523,75

ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH

Germany

EU Contribution

€ 2 647 171,25

UNIVERSITA DEGLI STUDI DI SASSARI

Italy

EU Contribution

€ 391 250

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA

Spain

EU Contribution

€ 1 597 781,25

UNIVERSITY OF NORTHUMBRIA AT NEWCASTLE

United Kingdom

EU Contribution

€ 434 135,75

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 392 415

UNIVERSITA VITA-SALUTE SAN RAFFAELE

Italy

EU Contribution

€ 705 980

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 511 875

IXSCIENT LIMITED

United Kingdom

EU Contribution

€ 464 000

MCROBERTS BV

Netherlands

EU Contribution

€ 592 187,50

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 1 126 930

PENUMOLOGISCHES FORSCHUNGSINSTITUTAN DER LUNGENCLINIC GROSSHANSDORF GMBH

Germany

EU Contribution

€ 796 412,50

CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER

France

EU Contribution

€ 514 685

AMGEN LIMITED

United Kingdom

ASTRAZENECA AB

Sweden

Bayer

Germany

ERESEARCH TECHNOLOGY INC

United States

GRUENENTHAL GMBH

Germany

ICON CLINICAL RESEARCH LIMITED

Ireland

MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

Germany

NOVARTIS PHARMA AG

Switzerland

PFIZER LIMITED

United Kingdom

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

TAKEDA DEVELOPMENT CENTRE EUROPE LTD.

United Kingdom

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Israel

Project information

Grant agreement ID: 820820

Status

Ongoing project

  • Start date

    1 April 2019

  • End date

    31 March 2024

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 49 361 564

  • EU contribution

    € 25 395 897

Coordinated by:

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom